<p>Aquestive Therapeutics（纳斯达克：AQST - 获取免费报告）在周五向投资者发布的一份报告中，研究分析师 Piper Sandler 将其目标价格从 5.00 美元上调至 8.00 美元，Benzinga 报道。该券商目前对该股票给予 “超配” 评级。Piper Sandler 的目标价格暗示该公司当前价格有 30.51% 的潜在上涨空间。</p>
<p>其他分析师最近也对该股票发布了研究报告。Zacks Research 在 10 月 17 日的研究报告中将 Aquestive Therapeutics 的评级从 “持有” 上调至 “强力买入”。花旗集团在 10 月 9 日的报告中重申了对 Aquestive Therapeutics 的 “跑赢大盘” 评级。Oppenheimer 在 9 月 8 日的研究报告中将 Aquestive Therapeutics 的目标价格从 7.00 美元上调至 8.00 美元，并给予该股票 “跑赢大盘” 评级。Weiss Ratings 在 10 月 8 日的报告中重申了对 Aquestive Therapeutics 的 “卖出（d-）” 评级。最后，JMP Securities 在 10 月 9 日的研究报告中将 Aquestive Therapeutics 的目标价格从 9.00 美元上调至 12.00 美元，并给予该公司 “市场跑赢” 评级。有两位分析师给予该股票 “强力买入” 评级，八位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Aquestive Therapeutics 的平均评级为 “买入”，共识目标价格为 10.00 美元。</p>
<p>获取 <strong>Aquestive Therapeutics</strong> 的提醒：</p>
<p><strong>阅读我们最新的 AQST 股票分析</strong></p>
<h2>Aquestive Therapeutics 股价上涨 2.2%</h2>
<p>AQST 的股票在周五以 6.13 美元开盘。该公司的市值为 6.1128 亿美元，市盈率为-8.63，贝塔值为 1.79。Aquestive Therapeutics 的 12 个月低点为 2.12 美元，12 个月高点为 7.55 美元。该股票的 50 日移动平均线为 5.84 美元，200 日移动平均线为 4.24 美元。</p>
<p>Aquestive Therapeutics（纳斯达克：AQST - 获取免费报告）最后一次公布财报是在 11 月 5 日，报告显示该公司本季度每股收益（EPS）为-0.14 美元，低于分析师一致预期的-0.13 美元，差额为 0.01 美元。该公司本季度的收入为 1281 万美元，而分析师预期为 1294 万美元。Aquestive Therapeutics 已设定其 2025 财年的每股收益指导。股票研究分析师预测，Aquestive Therapeutics 在本年度将发布-0.46 的每股收益。</p>
<h2>内部人士买卖情况</h2>
<p>在相关消息中，内部人士 Carl N. Kraus 在 10 月 15 日的交易中出售了 20,272 股该股票。该股票以平均价格 7.00 美元出售，总价值为 141,904.00 美元。交易后，该内部人士持有该公司 282,475 股股票，价值 1,977,325 美元。这代表其持股比例减少了 6.70%。该交易已在 SEC 的备案中披露，相关信息可通过此链接获取。此外，内部人士 Peter E. Boyd 在 9 月 5 日的交易中出售了 15,000 股该公司的股票。该股票以平均价格 5.30 美元出售，总价值为 79,500.00 美元。出售后，该内部人士直接持有该公司 288,323 股股票，价值 1,528,111.90 美元。此交易代表其持股比例减少了 4.95%。该出售的披露信息可在 SEC 备案中找到。在过去一个季度中，内部人士已出售 276,770 股公司股票，价值 1,692,203 美元。8.35% 的股票由公司内部人士持有。</p>
<h2>机构投资者对 Aquestive Therapeutics 的看法</h2>
<p>一些机构投资者和对冲基金最近买卖了 AQST 的股票。Geode Capital Management LLC 在第二季度将其在 Aquestive Therapeutics 的持股增加了 16.2%。Geode Capital Management LLC 现在拥有 1,977,001 股该公司的股票，价值 6,545,000 美元，此前在上个季度又购买了 276,295 股。Pale Fire Capital SE 在第二季度将其在 Aquestive Therapeutics 的持股增加了 25.5%。Pale Fire Capital SE 现在拥有 1,676,451 股该公司的股票，价值 5,549,000 美元，此前在此期间又购买了 340,767 股。Commonwealth Equity Services LLC 在第三季度获得了在 Aquestive Therapeutics 的新头寸，价值约为 5,918,000 美元。Sio Capital Management LLC 在第二季度将其在 Aquestive Therapeutics 的持股增加了 141.9%。Sio Capital Management LLC 现在拥有 947,489 股该公司的股票，价值 3,136,000 美元，此前在此期间又购买了 555,860 股。最后，Federated Hermes Inc.在第三季度获得了在 Aquestive Therapeutics 的新股份，价值 4,381,000 美元。32.45% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Aquestive Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Aquestive Therapeutics, Inc.是一家在美国及国际上运营的制药公司。该公司销售 Sympazan，一种用于治疗 Lennox-Gastaut 综合症的口服可溶膜制剂；Suboxone，一种用于治疗阿片类药物依赖的舌下膜制剂；Zuplenz，一种用于治疗与化疗和术后恢复相关的恶心和呕吐的口服可溶膜制剂；以及 Azstarys，一种用于治疗注意力缺陷多动障碍的每日一次产品。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Aquestive Therapeutics 更好</li>
<li>如何计算股票利润</li>
<li>为什么投资者不应害怕微软股票的下跌</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>DigitalOcean 的潮流已经转变：准备迎接浪潮</li>
<li>如何购买黄金股票并投资黄金</li>
<li>CAVA 股票在财报失利后寻找方向</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVFTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVFTVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Aquestive Therapeutics 吗？</h2>
<p>在考虑 Aquestive Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Aquestive Therapeutics 并不在名单上。</p>
<p>虽然目前分析师对 Aquestive Therapeutics 的评级为买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AQST

<p>Piper Sandler 将 Aquestive Therapeutics (NASDAQ:AQST) 的目标股价从 5.00 美元上调至 8.00 美元，维持 “增持” 评级。这表明与当前价格相比，潜在上涨幅度为 30.51%。其他分析师也上调了评级，Zacks 从 “持有” 调整为 “强力买入”。该股票开盘价为 6.13 美元，市值为 6.1128 亿美元。近期内部人士的销售和机构投资表明该股票的活跃交易，平均评级为 “买入”，共识目标价为 10.00 美元</p>

<p>Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) had its price objective increased by research analysts at Piper Sandler from $5.00 to $8.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an &#34;overweight&#34; rating on the stock. Piper Sandler's price objective would suggest a potential upside of 30.51% from the company's current price.</p>
<div class="lb-trans"><p>Aquestive Therapeutics（纳斯达克：AQST - 获取免费报告）在周五向投资者发布的一份报告中，研究分析师 Piper Sandler 将其目标价格从 5.00 美元上调至 8.00 美元，Benzinga 报道。该券商目前对该股票给予 “超配” 评级。Piper Sandler 的目标价格暗示该公司当前价格有 30.51% 的潜在上涨空间。</p>
</div><p>Other analysts have also recently issued research reports about the stock. Zacks Research raised shares of Aquestive Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Friday, October 17th. Citigroup reissued an &#34;outperform&#34; rating on shares of Aquestive Therapeutics in a report on Thursday, October 9th. Oppenheimer lifted their price target on Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an &#34;outperform&#34; rating in a research note on Monday, September 8th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Aquestive Therapeutics in a report on Wednesday, October 8th. Finally, JMP Securities lifted their price target on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the company a &#34;market outperform&#34; rating in a research report on Thursday, October 9th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Aquestive Therapeutics has an average rating of &#34;Buy&#34; and a consensus price target of $10.00.</p>
<div class="lb-trans"><p>其他分析师最近也对该股票发布了研究报告。Zacks Research 在 10 月 17 日的研究报告中将 Aquestive Therapeutics 的评级从 “持有” 上调至 “强力买入”。花旗集团在 10 月 9 日的报告中重申了对 Aquestive Therapeutics 的 “跑赢大盘” 评级。Oppenheimer 在 9 月 8 日的研究报告中将 Aquestive Therapeutics 的目标价格从 7.00 美元上调至 8.00 美元，并给予该股票 “跑赢大盘” 评级。Weiss Ratings 在 10 月 8 日的报告中重申了对 Aquestive Therapeutics 的 “卖出（d-）” 评级。最后，JMP Securities 在 10 月 9 日的研究报告中将 Aquestive Therapeutics 的目标价格从 9.00 美元上调至 12.00 美元，并给予该公司 “市场跑赢” 评级。有两位分析师给予该股票 “强力买入” 评级，八位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Aquestive Therapeutics 的平均评级为 “买入”，共识目标价格为 10.00 美元。</p>
</div><p>Get <strong>Aquestive Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aquestive Therapeutics</strong> 的提醒：</p>
</div><p><strong>Read Our Latest Stock Analysis on AQST</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 AQST 股票分析</strong></p>
</div><h2>Aquestive Therapeutics Trading Up 2.2%</h2>
<div class="lb-trans"><h2>Aquestive Therapeutics 股价上涨 2.2%</h2>
</div><p>Shares of AQST opened at $6.13 on Friday. The firm has a market cap of $611.28 million, a P/E ratio of -8.63 and a beta of 1.79. Aquestive Therapeutics has a 12 month low of $2.12 and a 12 month high of $7.55. The stock's 50 day moving average is $5.84 and its two-hundred day moving average is $4.24.</p>
<div class="lb-trans"><p>AQST 的股票在周五以 6.13 美元开盘。该公司的市值为 6.1128 亿美元，市盈率为-8.63，贝塔值为 1.79。Aquestive Therapeutics 的 12 个月低点为 2.12 美元，12 个月高点为 7.55 美元。该股票的 50 日移动平均线为 5.84 美元，200 日移动平均线为 4.24 美元。</p>
</div><p>Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). The firm had revenue of $12.81 million during the quarter, compared to analysts' expectations of $12.94 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts forecast that Aquestive Therapeutics will post -0.46 EPS for the current year.</p>
<div class="lb-trans"><p>Aquestive Therapeutics（纳斯达克：AQST - 获取免费报告）最后一次公布财报是在 11 月 5 日，报告显示该公司本季度每股收益（EPS）为-0.14 美元，低于分析师一致预期的-0.13 美元，差额为 0.01 美元。该公司本季度的收入为 1281 万美元，而分析师预期为 1294 万美元。Aquestive Therapeutics 已设定其 2025 财年的每股收益指导。股票研究分析师预测，Aquestive Therapeutics 在本年度将发布-0.46 的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖情况</h2>
</div><p>In related news, insider Carl N. Kraus sold 20,272 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $7.00, for a total value of $141,904.00. Following the transaction, the insider owned 282,475 shares of the company's stock, valued at $1,977,325. This represents a 6.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Peter E. Boyd sold 15,000 shares of the firm's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $5.30, for a total value of $79,500.00. Following the sale, the insider directly owned 288,323 shares in the company, valued at $1,528,111.90. This trade represents a 4.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 276,770 shares of company stock worth $1,692,203. 8.35% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Carl N. Kraus 在 10 月 15 日的交易中出售了 20,272 股该股票。该股票以平均价格 7.00 美元出售，总价值为 141,904.00 美元。交易后，该内部人士持有该公司 282,475 股股票，价值 1,977,325 美元。这代表其持股比例减少了 6.70%。该交易已在 SEC 的备案中披露，相关信息可通过此链接获取。此外，内部人士 Peter E. Boyd 在 9 月 5 日的交易中出售了 15,000 股该公司的股票。该股票以平均价格 5.30 美元出售，总价值为 79,500.00 美元。出售后，该内部人士直接持有该公司 288,323 股股票，价值 1,528,111.90 美元。此交易代表其持股比例减少了 4.95%。该出售的披露信息可在 SEC 备案中找到。在过去一个季度中，内部人士已出售 276,770 股公司股票，价值 1,692,203 美元。8.35% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Aquestive Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Aquestive Therapeutics 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of AQST. Geode Capital Management LLC raised its holdings in shares of Aquestive Therapeutics by 16.2% in the second quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company's stock valued at $6,545,000 after buying an additional 276,295 shares during the last quarter. Pale Fire Capital SE lifted its stake in shares of Aquestive Therapeutics by 25.5% in the second quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company's stock valued at $5,549,000 after purchasing an additional 340,767 shares during the period. Commonwealth Equity Services LLC acquired a new position in Aquestive Therapeutics during the third quarter valued at approximately $5,918,000. Sio Capital Management LLC grew its stake in Aquestive Therapeutics by 141.9% during the second quarter. Sio Capital Management LLC now owns 947,489 shares of the company's stock worth $3,136,000 after buying an additional 555,860 shares during the period. Finally, Federated Hermes Inc. acquired a new stake in Aquestive Therapeutics during the 3rd quarter valued at $4,381,000. 32.45% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近买卖了 AQST 的股票。Geode Capital Management LLC 在第二季度将其在 Aquestive Therapeutics 的持股增加了 16.2%。Geode Capital Management LLC 现在拥有 1,977,001 股该公司的股票，价值 6,545,000 美元，此前在上个季度又购买了 276,295 股。Pale Fire Capital SE 在第二季度将其在 Aquestive Therapeutics 的持股增加了 25.5%。Pale Fire Capital SE 现在拥有 1,676,451 股该公司的股票，价值 5,549,000 美元，此前在此期间又购买了 340,767 股。Commonwealth Equity Services LLC 在第三季度获得了在 Aquestive Therapeutics 的新头寸，价值约为 5,918,000 美元。Sio Capital Management LLC 在第二季度将其在 Aquestive Therapeutics 的持股增加了 141.9%。Sio Capital Management LLC 现在拥有 947,489 股该公司的股票，价值 3,136,000 美元，此前在此期间又购买了 555,860 股。最后，Federated Hermes Inc.在第三季度获得了在 Aquestive Therapeutics 的新股份，价值 4,381,000 美元。32.45% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Aquestive Therapeutics</h2>
<div class="lb-trans"><h2>关于 Aquestive Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.</p>
<div class="lb-trans"><p>Aquestive Therapeutics, Inc.是一家在美国及国际上运营的制药公司。该公司销售 Sympazan，一种用于治疗 Lennox-Gastaut 综合症的口服可溶膜制剂；Suboxone，一种用于治疗阿片类药物依赖的舌下膜制剂；Zuplenz，一种用于治疗与化疗和术后恢复相关的恶心和呕吐的口服可溶膜制剂；以及 Azstarys，一种用于治疗注意力缺陷多动障碍的每日一次产品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Aquestive Therapeutics</li>
<li>How to Calculate Stock Profit</li>
<li>Why Investors Shouldn’t Fear the Dip in Microsoft Stock</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>DigitalOcean’s Tide Has Turned: Get Ready to Ride the Wave</li>
<li>How to Buy Gold Stock and Invest in Gold</li>
<li>CAVA Stock Looking for Direction After Earnings Miss</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Aquestive Therapeutics 更好</li>
<li>如何计算股票利润</li>
<li>为什么投资者不应害怕微软股票的下跌</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>DigitalOcean 的潮流已经转变：准备迎接浪潮</li>
<li>如何购买黄金股票并投资黄金</li>
<li>CAVA 股票在财报失利后寻找方向</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVFTVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=AQST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Aquestive Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Aquestive Therapeutics 吗？</h2>
</div><p>Before you consider Aquestive Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Aquestive Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Aquestive Therapeutics 并不在名单上。</p>
</div><p>While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然目前分析师对 Aquestive Therapeutics 的评级为买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Aquestive Therapeutics（NASDAQ:AQST）被派杰公司给予新的 8.00 美元目标价